High Fives All Around as Merck Takes Down Cubist
Research - Merck is buying Cubist for $102/share, valuing the antibiotics company at $9.5B including its cash. After the close on Monday, the U.S. District Court in Delaware … Continue Reading
PremiumSearch Results for cubist
Cubist Goes to Merck: Yet Another Acquisition in Antibiotics
zFree - 2014 has already been a year of M&A records in the biopharmaceutical industry, and on Monday December 8 yet another major transaction occurred, this time … Continue Reading
Read now
Antibiotic Incentives Loom, Cubist Still Positioned to Benefit
Research - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read now
Cubist Set for a Solid 2014 with Pipeline Progress
Research - Since we last profiled Cubist Pharmaceuticals (CBST) in August, shares of the antibiotics company have posted a somewhat muted performance, rising less than 8% versus … Continue Reading
Read nowCubist Pharmaceuticals’ Strategic Acquisitions Are Great for Investors
Long Ideas - Since we initiated coverage of Cubist Pharmaceuticals (CBST) in mid-May, shares of the antibiotics manufacturer are up over 26%, as the company secured a key … Continue Reading
Read nowCubist Commands the Courtroom: Investors Can Now Focus On Long-Term Story
Long Ideas - Things are looking up for Cubist Pharmaceuticals (CBST). As we speculated last week, a key piece of Cubist’s ongoing litigation with Hospira has gone in … Continue Reading
Read nowMarkman Hearing A Likely Clearing Event For Cubist: Decision Any Day
Long Ideas - Shares of Cubist Pharmaceuticals (CBST) have not significantly participated in the market rally, and relative to biotech peers, CBST has lagged on performance as well; … Continue Reading
Read now